Pasithea Therapeutics Stock (NASDAQ: KTTA)

Dernières nouvelles pour Pasithea Therapeutics (NASDAQ:KTTA) Stock

Pasithea Therapeutics

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics Corp

B of A Securities analyst Ruplu Bhattacharya maintains Jabil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) with a Buy and raises the price target from $135 to $150.

News

Price Target

Analyst Ratings

B of A Securities Maintains Buy on Jabil, Raises Price Target to $150

TNXP

Tonix Pharmaceuticals Announces Issuance Of U.S. Patent Covering The Subcutaneous Delivery Of FDA-approved Zembrace Symtouch To Treat Migraines; New Patent Expected To Provide Market Exclusivity Into 2036

B of A Securities analyst Wamsi Mohan downgrades HP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) from Buy to Neutral and maintains the price target from $37 to $37.

Downgrades

B of A Securities Downgrades HP to Neutral, Maintains Price Target to $37

JMP Securities analyst Steven Delaney maintains Arbor Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABR#NYSE">ABR</a>) with a Market Outperform and raises the price target from $16 to $16.5.

JMP Securities Maintains Market Outperform on Arbor Realty Trust, Raises Price Target to $16.5

Concord Medical Reports Financial Results For 1H: Revenues Fell 23.1% YoY To $30.1M

Baird analyst Tristan Gerra maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Outperform and lowers the price target from $172 to $150.

Baird Maintains Outperform on Micron Technology, Lowers Price Target to $150

The Company will also present additional results from the Phase&nbsp;2 BEACON study for LYR-220 in adult patients with CRS who have had prior ethmoid sinus surgery at the Annual Meeting of the American Academy of Otolaryngology&ndash;Head and Neck Surgery (AAO-HNS), taking place September 28 - October 1 in Miami.

LYRA

Lyra Therapeutics Announced That The Company Will Present Results From The Phase 3 ENLIGHTEN 1 Study For LYR-210, The Company's Lead Product Candidate For CRS

Baird analyst David Koning maintains Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) with a Neutral and raises the price target from $350 to $370.

Baird Maintains Neutral on Accenture, Raises Price Target to $370

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life. 
&nbsp;
COPD is the most prevalent chronic respiratory disease in China, and is a priority within the government&#39;s Healthy China 2030 public health plan.
Dupixent is now approved in four indications across respiratory and dermatological diseases in China.

REGN

Regeneron Pharmaceuticals And Sanofi Today Announced That  National Medical Products Administration In China Has Approved Dupixent (Dupilumab) As An Add-on Maintenance Treatment For Adults With Uncontrolled Chronic Obstructive Pulmonary Disease

Baird analyst Ben Kallo maintains HA Sustainable (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HASI#NYSE">HASI</a>) with a Outperform and raises the price target from $36 to $47.

Hannon Armstrong Sustainable Infrastructure Capital

HASI

Baird Maintains Outperform on HA Sustainable, Raises Price Target to $47

Stephens &amp; Co. analyst Tommy Moll maintains ESCO Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESE#NYSE">ESE</a>) with a Overweight and raises the price target from $135 to $145.

Stephens & Co. Maintains Overweight on ESCO Technologies, Raises Price Target to $145

Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) announced it has received Pharmaceuticals and Medical Device Agency (PMDA) approval in&nbsp;Japan&nbsp;for the FARAPULSE&trade; Pulsed Field Ablation (PFA) System. The FARAPULSE PFA System, which is indicated for the isolation of pulmonary veins in the treatment of paroxysmal atrial fibrillation (AF), is a novel alternative to standard-of-care thermal ablation treatment.

Boston Scientific Receives Japanese Regulatory Approval For The FARAPULSE Pulsed Field Ablation System, Which Is Indicated For Isolation Of Pulmonary Veins In Treatment Of Paroxysmal Atrial Fibrillation

Baird analyst Ben Kallo maintains MP Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) with a Outperform and raises the price target from $20 to $25.

Baird Maintains Outperform on MP Materials, Raises Price Target to $25

Earnings

MITQ

Moving iMage Technologies Q4 Adj EPS $(0.04) Down From $(0.02) YoY, Sales $6.30M Up From $5.80M YoY

Stephens &amp; Co. analyst Mike Scialla maintains Matador Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTDR#NYSE">MTDR</a>) with a Overweight and raises the price target from $74 to $76.

MTDR

Stephens & Co. Maintains Overweight on Matador Resources, Raises Price Target to $76

Keybanc analyst Michael Leshock maintains Rocket Lab USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) with a Overweight and raises the price target from $8 to $11.

RKLB

Keybanc Maintains Overweight on Rocket Lab USA, Raises Price Target to $11

On September 26, 2024, Uber Technologies, Inc. (the &ldquo;Company&rdquo;) entered into a Credit Agreement (the &ldquo;Credit Agreement&rdquo;), among the Company, the lenders party thereto, the letter of credit issuers party thereto and Bank of America, N.A., as administrative agent. The Credit Agreement replaces the Company&rsquo;s existing Revolving Credit Agreement, dated as of June 26, 2015, among the Company, certain subsidiary guarantors from time to time party thereto, the lenders party thereto and Morgan Stanley Senior Funding, Inc., as administrative agent (as amended to date,&nbsp;the &ldquo;Existing Credit Agreement&rdquo;), which was terminated effective September 26, 2024.
&nbsp;
The Credit Agreement provides for $5.0 billion in aggregate amount of commitments for senior unsecured revolving loans, which will mature on September 26, 2029 unless otherwise extended in accordance with the terms of the Credit Agreement. The Credit Agreement provides that the Company may obtain, subject to the satisfaction of customary conditions, loans in U.S. Dollars or certain alternate currencies. Proceeds from any borrowings under the Credit Agreement may be used for general corporate purposes. The Credit Agreement is unsecured and is not guaranteed by any subsidiary of the Company.
&nbsp;
Loans under the Credit Agreement will bear interest, at the option of the Company, at either the term SOFR rate (determined in accordance with the Credit Agreement) plus an initial margin of 1.00% per annum or the base rate (determined in accordance with the Credit Agreement) plus an initial margin of 0.00% per annum. The Credit Agreement has a commitment fee, which will initially accrue at a rate of 0.125% per annum, on the actual daily undrawn amount of the aggregate commitments of the lenders in respect to the Credit Agreement. The applicable margin over the term SOFR rate and the base rate, as well as the commitment fee, will fluctuate based upon the ratings of the Company&rsquo;s non-credit enhanced senior unsecured long-term debt by Standard &amp; Poor&rsquo;s Financial Services LLC, Moody&rsquo;s Investors Service, Inc. or Fitch Ratings Ltd.
&nbsp;
The Credit Agreement contains certain customary representations and warranties, affirmative and negative covenants and events of default. Negative covenants include, among others, certain limitations on the incurrence of liens securing indebtedness by the Company and its material subsidiaries and the incurrence of indebtedness by the Company&rsquo;s material subsidiaries. In addition, the Credit Agreement requires that the Company maintain a ratio of consolidated adjusted earnings before interest, taxes, depreciation and amortization to consolidated interest expense of not less than 3.00 to 1.00, as more fully described in the Credit Agreement. The following events are considered &ldquo;events of default&rdquo; under the Credit Agreement: default in the payment of principal of any loan or any letter of credit obligation; default in the payment of any interest on any loan or on any letter of credit obligation, any fee due or any other amount payable thereunder and such default continues for a period of five business days; failure to comply with specified covenants; material misrepresentations; certain defaults by the Company or any of the Company&rsquo;s material subsidiaries with respect to indebtedness for borrowed money in an amount exceeding $300 million; certain events of bankruptcy, insolvency or reorganization of the Company, any of the Company&rsquo;s material subsidiaries (as defined in the Credit Agreement) or any of the Company&rsquo;s significant subsidiaries (as defined in the Credit Agreement); certain judgment defaults against the Company or any of the Company&rsquo;s material subsidiaries in an amount exceeding $300 million; the occurrence of certain ERISA events; and the occurrence of any change of control (as defined in the Credit Agreement). If certain bankruptcy and insolvency-related events of default occur any outstanding obligations under the Credit Agreement may be declared immediately due and payable and the commitments may be terminated. If an event of default, other than certain bankruptcy insolvency-related events of default, occur and are not cured within applicable grace periods or waived, any outstanding obligations under the Credit Agreement may be declared immediately due and payable and the commitments may be terminated.
&nbsp;
At closing, approximately $413 million of letters of credit have been issued under the Credit Agreement, transitioned from outstanding letters of credit under the Existing Credit Agreement, but no borrowings have been drawn.

UBER

Uber Technologies Enters A $5B Unsecured Revolving Credit Agreement With Bank Of America, Replacing Its Previous Credit Facility; The Agreement Will Mature On September 26, 2029

Keybanc analyst Justin Patterson downgrades Bumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) from Overweight to Sector Weight.

BMBL

Keybanc Downgrades Bumble to Sector Weight

Shares of Establishment Labs Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESTA#NASDAQ">ESTA</a>) rose sharply in today's pre-market as the company received U.S. FDA approval for Motiva Implants.
Establishment Labs Holdings shares jumped 28.3% to $52.88 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Fangdd Network Group Ltd.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUO#NASDAQ">DUO</a>) rose 51.3% to $1.62 in pre-market trading after jumping 110% on Thursday.</li>
<li>Onconetix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares rose 40.1% to $4.75 in pre-market trading. Onconetix recently announced a 1-for-40 reverse stock split.</li>
<li>The Real Good Food Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGF#NASDAQ">RGF</a>) gained 38.9% to $0.5140 in pre-market trading after announcing debt refinancing transactions with PMC Financial Services and Emblem Investment Fund for a $60 million new term loan.</li>
<li>Expion360 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) rose 30.2% to $0.0840 in pre-market trading after declining around 23% on Thursday.</li>
<li>Cardio Diagnostics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) shares rose 26.5% to $0.3162 in pre-market trading after falling around 5% on Thursday.</li>
<li>Mercurity Fintech Holding Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>) shares surged 16% to $1.60 in pre-market trading after falling around 4% on Thursday.</li>
<li>Sonim Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>) shares gained 10.1% to $3.27 in pre-market trading. Sonim Technologies recently announced a strategic distribution partnership with TCCM.</li>
<li>IonQ, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NASDAQ">IONQ</a>) gained 7% to $8.62 in pre-market trading after the company said it inked $54.5 million contract with the United States Air Force Research Lab.</li>
<li>Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) shares jumped 6.3% to $53.29 in pre-market trading as the company said the U.S. FDA has approved COBENFY&#x2122; (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Volato Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NYSE">SOAR</a>) shares dipped 19% to $0.4156 in pre-market trading after jumping 83% on Thursday.</li>
<li>enVVeno Medical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) fell 16.4% to $3.76 in pre-market trading after announcing a proposed public offering.</li>
<li>Momentus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>) shares fell 16% to $0.4504 in pre-market trading after the company received non-compliance notice from Listing Qualifications Department of Nasdaq.</li>
<li>Mustang Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) fell 13.8% to $0.2058 in pre-market trading after gaining more than 7% on Thursday.</li>
<li>Telesis Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) shares declined 12.8% to $3.48 in pre-market trading. Telesis Bio shares jumped 72% on Thursday after the company announced a partnership with Beckman Coulter Life Sciences to revolutionize DNA and mRNA synthesis.</li>
<li>Theriva Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#NASDAQ">TOVX</a>) shares fell 11.8% to $1.80 in pre-market trading after the company announced the pricing of $2.5 million public offering.</li>
<li>Cassava Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) declined 10.8% to $28.40 in pre-market trading after the SEC charged the company, two former executives for misleading claims about Alzheimer&#8217;s clinical trial.</li>
<li>AtlasClear Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATCH#NASDAQ">ATCH</a>) shares declined 9.8% to $0.2643 in pre-market trading.</li>
<li>Gryphon Digital Mining, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) fell 9.6% to $0.5533 in today's pre-market trading after gaining 10% on Thursday.</li>
<li>HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) shares fell 3.2% to $35.70 in pre-market trading after gaining over 2% on Thursday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/41061511/costco-scholastic-and-3-stocks-to-watch-heading-into-friday">Costco, Scholastic And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>

Markets

Movers

Trading Ideas

ATCH

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

ESTA

GRYP

IONQ

MBIO

MNTS

NVNO

ONCO

SAVA

SOAR

SONM

TBIO

TOVX

XPON

Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Enlivex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENLV#NASDAQ">ENLV</a>) with a Buy and maintains $6 price target.

Reiteration

ENLV

HC Wainwright & Co. Reiterates Buy on Enlivex Therapeutics, Maintains $6 Price Target

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pasithea Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) stock is falling on Wednesday after the company&rsquo;s shares experienced major volatility on Tuesday.



Investors watching KTTA stock will note that it closed out Tuesday up less than 1%. However, in earlier trading that day the stock saw <a href="https://investorplace.com/2023/12/why-is-pasithea-therapeutics-ktta-stock-up-105-today/">gains of more than 100%</a>.



So what happened?



Pasithea Therapeutics saw its shares rally in early morning trading on Tuesday alongside results from two preclinical trials. That came with heavy trading pushing the shares higher. However, it was unable to maintain that increased price.



It&rsquo;s possible that this has to do with KTTA being a penny stock. That opens it up to vulnerabilities, such as extreme volatility. It could be that day traders latched onto the stock yesterday alongside the study news and then sold their shares when prices peaked.



<h2>KTTA Stock Movement on Wednesday</h2>



As for KTTA stock movement today, the company&rsquo;s shares are down 11.8% during pre-market trading on Wednesday. That comes as some 31,000 shares change hands, as compared to its daily average of about 1.7 million shares.



Investors seeking out even more of the most recent stock market stories will want to stick around!



We have all of the hottest stock market news worth reading about on Wednesday! That includes everything happening with shares of Loop Media&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/lptv-stock-quote/">LPTV</a>) stock, Innovative International&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ioac-stock-quote/">IOAC</a>) stock and RiskOn International&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/roi-stock-quote/">ROI</a>) stock this morning. All of that news is available at the following links!



<h2>More Stock Market News for Wednesday</h2>



<ul><li><a href="https://investorplace.com/2023/12/why-is-loop-media-lptv-stock-down-16-today/">Why Is Loop Media (LPTV) Stock Down 16% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-innovative-international-ioac-stock-up-31-today/">Why Is Innovative International (IOAC) Stock Up 31% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-riskon-international-roi-stock-up-28-today/">Why Is RiskOn International (ROI) Stock Up 28% Today?</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;<a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a>&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;&nbsp;<a href="http://investorplace.com/" target="_blank">InvestorPlace.com</a>&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.&nbsp;



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/why-is-pasithea-therapeutics-ktta-stock-down-12-today/">Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ReShape Lifesciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/rsls-stock-quote/">RSLS</a>) stock is rising higher on Wednesday following approval from the Food and Drug Administration (FDA) for <a href="https://finance.yahoo.com/news/reshape-lifesciences-receives-fda-pma-210500500.html">a PMA supplement</a>.



That a PMA supplement applies to the company&rsquo;s Lap-Band 2.0 FLEX. This is the company&rsquo;s minimally invasive, long-term treatment of obesity.



Paul Hickey, president and CEO of ReShape Lifesciences, explains the differences the come with its updated Lap-Band 2.0 FLEX product.




&ldquo;Compared to our current Lap-Band, the Lap-Band&reg; 2.0 has a new feature called FLEX Technology, which acts as a relief valve, allowing larger pieces of food to more easily pass through the narrowed passage (or stoma), created by the band. Specifically, the band momentarily relaxes before returning to its resting diameter, therefore, minimizing discomfort caused by passage of large food pieces through the stoma.&rdquo;




<h2>What This Means for RSLS Stock</h2>



Improvement of its weight loss product is a positive for ReShape Lifesciences. The FDA approval also allows puts it closer to market, which could mean more revenue for the company.



With this news comes heavy trading of RSLS stock. As of this writing, around 50 million shares have changed hands. That&rsquo;s a massive leap in trading volume compared to the company&rsquo;s daily average of about 4 million shares.



RSLS stock is up 67.7% as of Wednesday morning.



There&rsquo;s more stock market news worth reading about below!



We have all of the hottest stock market news traders need to know about on Wednesday! Among that is what&rsquo;s happening with shares of Pasithea Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>), Loop Media&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/lptv-stock-quote/">LPTV</a>)&nbsp;and Innovative International&nbsp;Acquisition&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ioac-stock-quote/">IOAC</a>) stock. You can find out more on these matters down below!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2023/12/why-is-pasithea-therapeutics-ktta-stock-down-12-today/">Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-loop-media-lptv-stock-down-16-today/">Why Is Loop Media (LPTV) Stock Down 16% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-innovative-international-ioac-stock-up-31-today/">Why Is Innovative International (IOAC) Stock Up 31% Today?</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;<a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a>&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;&nbsp;<a href="http://investorplace.com/" target="_blank">InvestorPlace.com</a>&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.&nbsp;



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/why-is-reshape-lifesciences-rsls-stock-up-68-today/">Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Palantir Technologies (NYSE:<a href="https://investorplace.com/stock-quotes/pltr-stock-quote/">PLTR</a>) stock is in the news Wednesday after the big data company <a href="https://finance.yahoo.com/news/palantir-renews-digital-transformation-partnership-115900977.html">renewed a contract</a> with UniCredit.



According to a press release from Palantir, UniCredit has renewed its partnership with the company for another five years. That will see it make use of the Palantir Foundry operating system to enhance its digital transformation.



Investors will note that Palantir and UniCredit first started working together in 2018. Over those five years, UniCredit saw significant benefits from the Palantir Foundry operating system. That even resulted in it expanding the use of the technology to all CE&amp;EE UniCredit Legal Entities.



Josh Harris, a Palantir executive, said the following about this partnership.




&ldquo;Palantir has long been a proud partner to some of the world&rsquo;s top financial institutions. We&rsquo;re honored that UniCredit has placed its confidence in Palantir once again and look forward to furthering the bank&rsquo;s digital transformation.&rdquo;




<h2>PLTR Stock Movement on Wednesday</h2>



With this recent news comes some 7 million shares of PLTR stock changing hands. That&rsquo;s still a ways off from its daily average trading volume of about 61 million shares. The stock is also down 1.3% as of Wednesday morning despite the renewed contract. However, PLTR is up 170.4% year-to-date.



Investors looking for more of the latest stock market news will want to keep reading!



We have all of the hottest stock market news worth checking out on Wednesday! A few examples of that include what&rsquo;s happening with ReShape Lifesciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rsls-stock-quote/">RSLS</a>), Pasithea Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) and Loop Media&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/lptv-stock-quote/">LPTV</a>) stock. You can find more on these matters below!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2023/12/why-is-reshape-lifesciences-rsls-stock-up-68-today/">Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-pasithea-therapeutics-ktta-stock-down-12-today/">Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-loop-media-lptv-stock-down-16-today/">Why Is Loop Media (LPTV) Stock Down 16% Today?</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/pltr-stock-palantir-renews-unicredit-partnership/">PLTR Stock: Palantir Renews UniCredit Partnership</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PLTR Stock: Palantir Renews UniCredit Partnership

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Roblox (NYSE:<a href="https://investorplace.com/stock-quotes/rblx-stock-quote/">RBLX</a>) stock is on the move Wednesday as investors react to new coverage of the video game company&rsquo;s shares from Wells Fargo.



Wells Fargo analysts <a href="https://www.investing.com/news/stock-market-news/roblox-ads-to-become-significant-earnings-stream-over-time--wells-fargo-432SI-3255780">initiated coverage of RBLX stock</a> with an &ldquo;overweight&rdquo; rating. To put that in perspective, the analysts&rsquo; consensus rating for RBLX shares is moderate buy based on 22 opinions.



In addition to that, the company started its coverage of RBLX stock with a price target of $49 per share. That represents a potential upside of 16.6%. It&rsquo;s also bullish next to the analysts&rsquo; consensus price prediction of <a href="https://www.marketbeat.com/stocks/NYSE/RBLX/price-target/">$41.62 per share</a>.



<h2>Why the Bull Rating for RBLX Stock?</h2>



Here&rsquo;s what the Wells Fargo analysts had to say about Roblox in a note to clients obtained by Investing.com.




&ldquo;Similar to other audience platforms, we expect ads to become a significant earnings stream over time for Roblox, supported by strong user engagement. See meaningful upside to consensus bookings and EBITDA as we believe the ads opportunity is underappreciated by the Street, which has yet to properly capture future ad bookings into forecasts.&rdquo;




RBLX stock is up 2.5% as of Wednesday morning. This comes with more than 3.8 million shares traded. For the record, the company&rsquo;s daily average trading volume is still above that at 10.5 million shares.



Investors who want more of the latest stock market news are in luck!



We&rsquo;ve got all of the hottest stock market stories that traders need to know about on Wednesday! That includes everything going on with Palantir Technologies&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/pltr-stock-quote/">PLTR</a>) stock, ReShape Lifesciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rsls-stock-quote/">RSLS</a>) stock and Pasithea Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) stock. You can find out more on these matters at the following links!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2023/12/pltr-stock-palantir-renews-unicredit-partnership/">PLTR Stock: Palantir Renews UniCredit Partnership</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-reshape-lifesciences-rsls-stock-up-68-today/">Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-pasithea-therapeutics-ktta-stock-down-12-today/">Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/rblx-stock-alert-wells-fargo-initiates-roblox-coverage-with-overweight-rating/">RBLX Stock Alert: Wells Fargo Initiates Roblox Coverage With &#8216;Overweight&#8217; Rating</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

RBLX Stock Alert: Wells Fargo Initiates Roblox Coverage With 'Overweight' Rating

Pasithea conducts 1-for-20 reverse stock split, gets FDA okay for study

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Friday as we get into all of the biggest news affecting shares on the final day of trading this week!



Moving stocks today are public offerings, an earnings report and more.



Let&rsquo;s dive into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Aclarion (NASDAQ:<a href="https://investorplace.com/stock-quotes/acon-stock-quote/">ACON</a>) stock is rocketing more than 79% alongside heavy pre-market trading.</li>



<li>Himalaya Shipping (NYSE:<a href="https://investorplace.com/stock-quotes/hshp-stock-quote/">HSHP</a>) shares are soaring over 21% without any clear news this morning.</li>



<li>Ekso Bionics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ekso-stock-quote/">EKSO</a>) stock is surging more than 20% with strong early morning trading.</li>



<li>Panbela Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/pbla-stock-quote/">PBLA</a>) shares are gaining over 19% as it prepares for a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318006293&amp;type=PDF&amp;symbol=PBLA&amp;cdn=255e23064a07775ab2cefc841a6dd3b1&amp;companyName=Panbela+Therapeutics+Inc.&amp;formType=S-1%2FA&amp;formDescription=%5BAmend%5D+General+form+for+registration+of+securities+under+the+Securities+Act+of+1933&amp;dateFiled=2024-01-25">proposed public offering</a>.</li>



<li>Ucommune International (NASDAQ:<a href="https://investorplace.com/stock-quotes/uk-stock-quote/">UK</a>) stock is increasing more than 18% on Friday morning.</li>



<li>The Real Brokerage (NASDAQ:<a href="https://investorplace.com/stock-quotes/reax-stock-quote/">REAX</a>) shares are rising over 18% after <a href="https://www.nasdaq.com/press-release/the-real-brokerage-invites-you-to-join-us-at-the-microcap-conference-2024-01-25">announcing a presentation next week</a>.</li>



<li>BIT Mining Limited (NYSE:<a href="https://investorplace.com/stock-quotes/btcm-stock-quote/">BTCM</a>) stock is climbing more than 16% on Friday.</li>



<li>Lixiang Education (NASDAQ:<a href="https://investorplace.com/stock-quotes/lxeh-stock-quote/">LXEH</a>) shares are getting an over 15% boost after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318005286&amp;type=PDF&amp;symbol=LXEH&amp;cdn=6639882602bf7fce8ca884d95ec782b1&amp;companyName=Lixiang+Education+Holding+Co.+Ltd.&amp;formType=6-K&amp;formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&amp;dateFiled=2024-01-25">regaining Nasdaq compliance</a>.</li>



<li>Porch Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/prch-stock-quote/">PRCH</a>) stock is jumping more than 14% <a href="https://www.nasdaq.com/press-release/porch-group-receives-%2425m-with-signing-of-strategic-agreement-with-aon-2024-01-25">alongside a strategic agreement</a>.</li>



<li>Pasithea Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) shares are up over 14% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Aptose Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/apto-stock-quote/">APTO</a>) stock is plummeting more than 26% as <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318008758&amp;type=PDF&amp;symbol=APTO&amp;cdn=12b3da5a3896f2a507db32324ce6eb5a&amp;companyName=Aptose+Biosciences+Inc.&amp;formType=EFFECT&amp;formDescription=Notice+of+Effectiveness&amp;dateFiled=2024-01-25">a public offering goes into effect</a>.</li>



<li>SU Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUGP#NASDAQ">SUGP</a>) shares are diving over 21% following its recent <a href="https://www.nasdaq.com/press-release/su-group-holdings-limited-announces-pricing-of-initial-public-offering-2024-01-23">initial public offering (IPO)</a>.</li>



<li>Eve&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/evex-stock-quote/">EVEX</a>) stock is tumbling more than 19% despite a lack of news.</li>



<li>Paramount Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/para-stock-quote/">PARA</a>) shares are retreating over 18% after <a href="https://investorplace.com/2024/01/para-stock-alert-is-david-ellison-about-to-take-paramount-global-private/">rising yesterday on acquisition reports</a>.</li>



<li>LAVA Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/lvtx-stock-quote/">LVTX</a>) stock is taking a more than 12% beating <a href="https://www.marketwatch.com/story/lava-therapeutics-shares-rise-as-drug-set-for-test-with-merck-s-keytruda-c936d7cd">after rallying yesterday</a>.</li>



<li>Nxu (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxu-stock-quote/">NXU</a>) shares are dropping over 12% after <a href="https://www.nasdaq.com/press-release/nxu-submits-for-nevi-grant-funding-to-enhance-its-major-highway-electrification-goals">seeking new grant funding</a>.</li>



<li>Sagimet Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/sgmt-stock-quote/">SGMT</a>) stock is decreasing more than 11% with <a href="https://finance.yahoo.com/news/sagimet-biosciences-announces-proposed-public-224500288.html">public offering plans</a>.</li>



<li>Integrated Media Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/imte-stock-quote/">IMTE</a>) shares are falling over 11% on Friday.</li>



<li>Intel (NASDAQ:<a href="https://investorplace.com/stock-quotes/intc-stock-quote/">INTC</a>) stock is sliding more than 10% with <a href="https://www.cnbc.com/2024/01/25/intel-intc-earnings-report-q4-2023.html">Q4 earnings results</a>.</li>



<li>Clearmind Medicine (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmnd-stock-quote/">CMND</a>) shares close out our pre-market stock movers down over 10%.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/01/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-jan-26th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pasithea Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) just reported results for the first quarter of 2024.<ul><li>Pasithea Therapeutics reported earnings per share of -$3.70.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/ktta-stock-earnings-pasithea-therapeutics-for-q1-of-2024/">KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q1 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pasithea Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) just reported results for the fourth quarter of 2023.<ul><li>Pasithea Therapeutics reported earnings per share of -$4.10.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/06/ktta-stock-earnings-pasithea-therapeutics-for-q4-of-2023/">KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q4 2023

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pasithea Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) just reported results for the second quarter of 2024.<ul><li>Pasithea Therapeutics reported earnings per share of -$3.71.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ktta-stock-earnings-pasithea-therapeutics-for-q2-of-2024/">KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q2 2024

Pasithea Therapeutics drops 19% on $5M private placement

ACON

APTO

BTCM

CMND

EKSO

EVEX

HSHP

IMTE

INTC

IOAC

KTTA

KTTAW

LPTV

LVTX

LXEH

PARA

PBLA

PLTR

PRCH

RBLX

REAX

RSLS

SGMT

SUGP

Press Releases

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Health Care

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

General

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Comments

Pasithea Therapeutics

Actualités

Dernières nouvelles pour Pasithea Therapeutics (NASDAQ:KTTA) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL